NVCT
Nuvectis Pharma, Inc. (NASDAQ)
Healthcare — Biotechnology
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Price History
Fundamentals
| Market Cap | $615.38M |
| P/E Ratio (TTM) | - |
| Forward P/E | -20.33 |
| EPS (TTM) | $-1.31 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -154.43% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $29.20 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 64.9 |
| Beta | -0.07 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $29.28 |
| 52-Week Low | $5.55 |
| 50-Day Avg | $12.14 |
| 200-Day Avg | $8.63 |
| Avg Volume | 277.9K |
| Volume | 157.2K |
Performance Analysis
BULLISHNVCT shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report